Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back
ViewAttendees 19

Exhibitor Tutorial

Innovative automation solutions for 3D cell biology, single-cell insights and proteomics workflows

Tuesday, February 6, 2024
8:30 AM – 10:00 AM EST
Room/Location:  151A

Sponsored By 
Food/Beverage Available Exhibitor Tutorial Prize Quest
Alexander Schmidt, Proteomics Core Facility Head at the University of Basel in Switzerland will discuss his work with a large variety of different samples and applications. He will provide an overview about improvements to his daily work provided by Tecan automated solutions. These Tecan improvements include:
  • Automatic measurement of protein and peptide concentrations using the Tecan M-Plex®;
  • Automatic reduction, alkylation, proteolysis and cleanup of protein lysates for LC-MS analysis using Tecan's Resolvex® A200 in combination with the iST workflow from PreOmics;
  • Automatic reduction, alkylation, proteolysis and cleanup of protein lysates for LC-MS analysis using Tecan EVO® in combination with the SP3 workflow from PreOmics;
  • Automatic labeling of peptide samples with tandem mass tags (TMT 16-plex) for discovery proteomics.
Schmidt will also provide an outlook of the workflows he is currently setting up on his new Tecan Fluent® automated workstation, focusing on the improvements that can be achieved with this new liquid handling system.

Automated single cell proteomics workflow to study drugs responses.Bogdan Budnik, Principal Scientist at the Wyss Institute at Harvard University will present the findings on behalf of a team including the following individuals:

Michael Lewandowski1, Shad Morton1, Mariana Garcia-Corral1, Katharina Meyer1, Jenny M. Tam1,2, Rushdy Ahmad1, George M. Church1,2,3, David R. Walt1,2, 4, Bogdan Budnik1Drug discovery and development are being transformed by single-cell technologies such as single-cell RNA sequencing (scRNA-seq). We can improve our understanding of disease mechanisms by using cell subtyping to identify targets. Proteomics data at a single cell resolution are necessary due to the lack of correlation between RNA and protein abundances.In its early stages, single-cell proteomics (SCP) was used to study cancer cell monocultures and their response to drug treatments. For further analysis of proteome heterogeneity of very complex cell mixtures as brain organoids, we developed an automated workflow that can prepare single cells. We have demonstrated that different classes of drug treatments result in unique cell responses, and our findings indicate that single-cell proteomics provides important data that can be used to uncover novel biology processes that can lead to better treatments by revealing complex biological systems.Our technique was validated by treating human induced pluripotent stem cells (hiPSCs) derived from healthy and bipolar patients with three different drugs.  Cells were grown both mono-cultured and co-cultured. Compared to bulk proteomics, single-cell proteomics revealed inherent heterogeneity in cell populations and differences in drug response. We observed subpopulations of cells with unique drug response profiles.  Hence, SCP analysis is necessary to understand the effects of drugs under different disease states, and discoveries made from single-cell data can lead to effective treatments for this disease that are greatly needed.

  1. Wyss Institute at Harvard University, Boston, MA, USA
  2. Harvard Medical School, Boston, MA, USA
  3. Department of Genetics, Harvard University, Cambridge, MA, USA
  4. Brigham and Women’s Hospital, Boston, MA, USA
A PATIENT IN THE LAB® platform for drug development, patient stratification, and predictive diagnosticsRené Overmeer, Head of Assay Development and Automation at HUB Organoids B.V. (HUB) in The Netherlands, will demonstrate further contributions to drug development, patient stratification and predictive diagnostics: Despite requiring a large investment to move drugs to clinical trials, the majority of new drugs fail in clinical trials. This is in large part due to the shortcomings of the standard models. In addition to poor correlation, highly innovative drugs lack relevant pre-clinical models.Patient-derived organoids (PDOs or HUB OrganoidsTM) are directly established from patient tissue, faithfully recapitulate patient disease and are proving to be a major breakthrough in pre-clinical models. Although PDOs greatly bridge the gap between the lab and the clinic and effectively bring a “patient in the lab”. adaptation of assays to the new model is not without challenges. HUB has developed a platform to perform various medium- to high-throughput screening assays and to develop complex (high content) screening assays.  HUB is involved in OPTIC, an ongoing prospective multicenter trial (NL61668.041.17, started 2018), to evaluate the value of tumor PDOs in therapy response prediction. Preliminary results are promising. PDO can be established from biopsies with a high success rate, their response correlates with patient response, can be readily expanded and are suitable for screening, making them a promising model for drug development.Accelerate your research. Scale clinical impact.Lesley Schultz, Director of Enterprise Customers and Cellomics-Proteomics at Tecan will provide an overview of how Tecan automations continue to accelerate discoveries with Tecan’s partners, scaling innovations from research to the clinic.